A Phase 2 interventional study of KAF156 in Malaria, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in 2 countries. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-06-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Malaria by Novartis — 3 open to participants now, 3 under way, none of them phase 3. Malaria · Novartis.
Among the 24 studies in Malaria by Novartis, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2013, is one of 6 in phase 2, and was the 10th registered.
1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →3 of the 24 studies in Malaria by Novartis are open now, in 6 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Burkina Faso, Côte D'Ivoire, Gabon and 3 more countries
Ages 2–100
Novartis Pharmaceuticals
Ages 0 days–12 mo
Novartis Pharmaceuticals
Ages 10–99 · Healthy volunteers
By country, each count listing its studies:
Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.
This study: 20 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 5 · Phase 4 5
First in 2001; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 252 across 938 interventional studies indexed under Malaria.
Median enrollment 57 across the 21 interventional studies, 254 across the 2 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Malaria by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07896746Novartis PharmaceuticalsFactors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Malaria by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAF156 at 400 mg/day (Part 1) and single dosing with KAF156 at 800mg (Part 2)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Male and female patients aged 20 to 60 years;Presence of mono-infection of P. falciparum or P. vivax; Weight between 40 kg to 90 kg.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.
Drug: KAF156
Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.
Drug: KAF156
Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.
Drug: KAF156
KAF156 was supplied as tablets for oral use.
Time to Parasite Clearance
Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and blood density assessments.
Time frame: Day 5
28-day Cure Rate - Part 2
28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment.
Time frame: Day 28
Area Under the Curve (AUC)0-24h - Part 1
AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose was taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Days 1 and 3
Maximum Concentration (Cmax) - Part 1
Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Days 1 and 3
Time to Maximum Concentration (Tmax) - Part 1
Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Days 1 and 3
Area Under the Curve (AUC)Last - Part 1
AUClast was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Day 3
Area Under the Curve (AUC)Inf - Part 1
AUCinf was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Day 3
Half-life (T1/2) - Part 1
T1/2 was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Day 3
Clearance (CL/F ) - Part 1
CL/F was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Day 3
Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) - Part 1
Vz/F was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Day 3
Accumulation Ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1) - Part 1
Racc was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Day 3
AUC0-24h - Part 2
AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.
Time frame: Day 1
AUC0-48h - Part 2
AUC0-48h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Day 1
AUClast - Part 2
AUClast was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose
Time frame: Day 1
AUCinf - Part 2
AUCinf was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose
Time frame: Day 1
Cmax - Part 2
Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.
Time frame: Day 1
Tmax - Part 2
Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.
Time frame: Day 1
T1/2 - Part 2
T1/2 was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Day 1
CL/F - Part 2
CL/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Day 1
Vz/F - Part 2
Vz/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
Time frame: Day 1
| Milestone | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|---|---|
| Started | 11 | 10 | 22 |
| Pharmacodynamic (pd) set | 10 | 10 | 21 |
| Pharmacokinetic(pk) set | 10 | 10 | 21 |
| Safety set | 11 | 10 | 22 |
| Intent-to-treat analysis set | 11 | 10 | 22 |
| Completed | 10 | 10 | 13 |
| Not completed | 1 | 0 | 9 |
| Withdrew: Lack of efficacy | 0 | 0 | 8 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 |
Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and blood density assessments.
| Hours | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|---|---|
| Time to Parasite Clearance | 23.63 (16.00 to 30.02) | 44.97 (36.25 to 47.98) | 48.75 (42.00 to 53.95) |
28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment.
| Percentage of participants | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|
| 28-day Cure Rate - Part 2 | 63.6 |
AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose was taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| (hr*ng/mL) | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD |
|---|---|---|
| Day 1 | 9470 ± 2140 | 10100 ± 2440 |
| Day 3 | 20200 ± 3730 | 21700 ± 6630 |
Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| ng/mL | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD |
|---|---|---|
| Day 1 | 795 ± 182 | 856 ± 158 |
| Day 3 | 1440 ± 299 | 1620 ± 384 |
Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| hour | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD |
|---|---|---|
| Day 1 | 3.00 (2.00 to 6.00) | 3.00 (1.00 to 4.03) |
| Day 3 | 3.00 (2.00 to 5.98) | 2.52 (2.00 to 3.02) |
AUClast was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| hr*ng/mL | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD |
|---|---|---|
| Area Under the Curve (AUC)Last - Part 1 | 55800 ± 12800 | 54300 ± 22500 |
AUCinf was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| hr*ng/mL | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD |
|---|---|---|
| Area Under the Curve (AUC)Inf - Part 1 | 58300 ± 14500 | 56700 ± 24800 |
T1/2 was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| hr | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD |
|---|---|---|
| Half-life (T1/2) - Part 1 | 39.0 ± 7.40 | 40.8 ± 8.37 |
CL/F was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| L/hr | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD |
|---|---|---|
| Clearance (CL/F ) - Part 1 | 20.4 ± 4.04 | 19.7 ± 5.12 |
Vz/F was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| Liters | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD |
|---|---|---|
| Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) - Part 1 | 1150 ± 286 | 1140 ± 288 |
Racc was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| ratio | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD |
|---|---|---|
| Accumulation Ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1) - Part 1 | 2.16 ± 0.256 | 2.15 ± 0.384 |
AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.
| hr*ng/mL | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|
| AUC0-24h - Part 2 | 21700 ± 5680 |
AUC0-48h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| hr*ng/mL | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|
| AUC0-48h - Part 2 | 33600 ± 9150 |
AUClast was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose
| hr*ng/mL | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|
| AUClast - Part 2 | 54900 ± 16600 |
AUCinf was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose
| hr*ng/mL | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|
| AUCinf - Part 2 | 58300 ± 18600 |
Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.
| ng/mL | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|
| Cmax - Part 2 | 1800 ± 404 |
Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.
| hours | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|
| Tmax - Part 2 | 3.52 (2.00 to 11.6) |
T1/2 was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| hours | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|
| T1/2 - Part 2 | 48.7 ± 7.85 |
CL/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| L/hr | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|
| CL/F - Part 2 | 15.1 ± 4.85 |
Vz/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.
| Liters | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|
| Vz/F - Part 2 | 1030 ± 264 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | — | 0/11 (0%) | 5/11 (45.5%) |
| Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | — | 0/10 (0%) | 8/10 (80%) |
| Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose | — | 0/22 (0%) | 22/22 (100%) |
| Event | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose |
|---|---|---|---|
| Sinus bradycardiaCardiac disorders | 1/11 | 3/10 | 14/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/11 | 1/10 | 13/22 |
| HypokalaemiaMetabolism and nutrition disorders | 0/11 | 1/10 | 11/22 |
| AnaemiaBlood and lymphatic system disorders | 0/11 | 1/10 | 7/22 |
| VomitingGastrointestinal disorders | 0/11 | 1/10 | 6/22 |
| Alanine aminotransferase increasedInvestigations | 1/11 | 1/10 | 5/22 |
| Decreased appetiteMetabolism and nutrition disorders | 0/11 | 1/10 | 5/22 |
| Abdominal painGastrointestinal disorders | 0/11 | 2/10 | 1/22 |
| NeutropeniaBlood and lymphatic system disorders | 0/11 | 0/10 | 4/22 |
| DiarrhoeaGastrointestinal disorders | 0/11 | 0/10 | 4/22 |
| Age, Continuous(Years) | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose | Total |
|---|---|---|---|---|
| Mean | 28.1 ± 8.42 | 36.7 ± 10.90 | 28.9 ± 7.00 | 31.2 ± 8.77 |
| Sex/Gender, Customized(Participants) | Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD | Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD | Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose | Total |
|---|---|---|---|---|
| Number | 11 | 10 | 22 | 43 |
The record gives a start of Mar 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ganaplacide